Using the Drug TIC10 to Treat Brain Cancer

A patent for using a specific small molecule drug called TIC10 to treat brain cancers like glioblastoma by triggering a natural cell-death process.

What it covers

This patent describes a method for treating brain cancer by administering a specific chemical compound known as TIC10. The compound works by inducing the expression of a protein called TRAIL, which signals cancer cells to undergo apoptosis, or programmed cell death. The claims cover using this drug alone or in combination with other anti-cancer or anti-angiogenic agents, such as bevacizumab, to fight tumors. It also includes methods for monitoring the treatment's success by measuring TRAIL levels in a patient's blood or cerebrospinal fluid.

What it doesn't cover

• —Does not cover the use of TIC10 for treating diseases other than cancer.
• —Does not cover chemical compounds that do not match the specific structure defined as Formula (I).
• —Does not cover general immunotherapy methods that do not rely on the specific TRAIL-induction mechanism of TIC10.
• —Does not cover diagnostic methods that do not involve assessing TRAIL levels as a marker for treatment effectiveness.

The clever bit

The innovation lies in identifying a small molecule that can cross the blood-brain barrier and specifically upregulate TRAIL, a protein that triggers suicide in cancer cells while often leaving healthy cells unharmed.

Why it matters

Glioblastoma is a highly aggressive form of brain cancer with limited treatment options. This patent represents a targeted approach to therapy, moving away from broad-spectrum chemotherapy toward drugs that activate the body's own cell-death pathways. It provides a legal framework for the development of TIC10 as a specialized pharmaceutical product.

Real-world examples

• 1.TIC10 (also known as ONC201) in clinical trials for glioblastoma
• 2.Combination therapies involving mitotic inhibitors like paclitaxel